^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    IL-2R agonist

    Related drugs:
    5d
    Rezpegaldesleukin (NKTR-358) in New Onset Type 1 Diabetes Mellitus (clinicaltrials.gov)
    P2, N=66, Recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Not yet recruiting --> Recruiting | Trial completion date: May 2029 --> May 2028 | Initiation date: Nov 2025 --> Mar 2026
    Enrollment open • Trial completion date • Trial initiation date
    1m
    A Phase II Study of ILKN421H With Pembrolizumab in Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, iLeukon Therapeutics, Inc.
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)
    2ms
    PH-ICKPD1-02/21: A phase 2 study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 Pembrolizumab, in stage III/IV unresectable melanoma patients with resistance to anti-PD1 checkpoint inhibitors (INTACT / MeRCI) (2024-519326-20-00)
    P1/2, N=65, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial • Checkpoint inhibition
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2ms
    PHL19IL2TNFCOMB04/24: L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) (2025-523229-16-00)
    P1/2, N=85, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2ms
    L19IL2/L19TNF in patients with cutaneous squamous cell carcinoma (2025-523231-19-00)
    P1/2, N=54, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    2ms
    L19IL2/TNF in patients with basal cell carcinoma (2025-523230-77-00)
    P1/2, N=53, Not yet recruiting, Philogen S.p.A.
    New P1/2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    4ms
    Neo-DREAM: Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients (clinicaltrials.gov)
    P3, N=186, Recruiting, Philogen S.p.A. | Trial completion date: Jun 2026 --> Dec 2031 | Trial primary completion date: Jun 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Nidlegy (darleukin/fibromun)
    4ms
    A Study to Evaluate Safety and Anti-Tumor Activity of Eciskafusp Alfa (RO7284755) Alone or in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=189, Completed, Hoffmann-La Roche | Active, not recruiting --> Completed | Trial completion date: Aug 2026 --> Oct 2025 | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    Tecentriq (atezolizumab) • eciskafusp alfa (RG6279)
    5ms
    L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    5ms
    L19IL2/TNF in Patients With Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=92, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    5ms
    L19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC) (clinicaltrials.gov)
    P2, N=180, Not yet recruiting, Philogen S.p.A.
    New P2 trial
    |
    Nidlegy (darleukin/fibromun) • darleukin (L19IL2)
    6ms
    PD-1-Cis IL-2R Agonism Determines the Predicted Pharmacological Dose Range for the Immunocytokine Eciskafusp Alfa (PD1-IL2v). (PubMed, CPT Pharmacometrics Syst Pharmacol)
    Furthermore, binding in cis-configuration is expected to follow a "bell-shaped" relationship with drug concentration such that high concentrations may lead to reduced benefit/risk ratio compared with concentrations around the peak of the bell-shape. Model simulations identify patient cohorts for whom the upper limit of the pharmacological dosing range may be defined by either undesirable off-tumor target engagement or a decrease in on-tumor cis-binding.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IL2RA (Interleukin 2 receptor, alpha)
    |
    eciskafusp alfa (RG6279)